combination therapy

Research in Review

Induction Therapy With Clofarabine Shows No Survival Benefit for AML

01/16/2017

JCP Editors

Adding clofarabine to standard induction therapy shows no effect on survival for patients with newly diagnosed acute myeloid leukemia (AML), according to a study published in Blood. Standard induction treatment with...

Adding...

01/16/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Without Chemotherapy May Treat Type of Lymphoma

01/06/2017

JCP Editors

Patients with mantle cell lymphoma may be able to forego chemotherapy in favor of induction treatment with a two-drug regimen, according to new research presented at the American Society of Hematology (ASH) annual...

...

01/06/2017

Journal of Clinical Pathways

Research in Review

Three-Drug Regimen Does Not Improve Prostate Cancer Survival

01/05/2017

JCP Editors

Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...

...

01/05/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Plus Bortezomib Improves Survival for Patients With Multiple Myeloma

12/29/2016

JCP Editors

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical...

The...

12/29/2016

Journal of Clinical Pathways

Research in Review

Proton Pump Inhibitors May Decrease Survival for Patients With Gastric Cancer

12/19/2016

JCP Editors

Over-the-counter heartburn and gastrointestinal drugs, such as proton pump inhibitors (PPIs), may decrease the effectiveness of chemotherapy in patients with gastroesophageal cancer (GEC), according to a new study...

...

12/19/2016

Journal of Clinical Pathways

Research in Review

Switching From Docetaxel to Paclitaxel and Bevacizumab Improves PFS in NSCLC

12/08/2016

JCP Editors

Patients with non-squamous non-small cell lung cancer (NSCLC) have improved progression-free survival (PFS) if they switch from docetaxel to paclitaxel and bevacizumab treatments, according to new...

...

12/08/2016

Journal of Clinical Pathways

Research in Review

11/30/2016

JCP Editors

Two kinds of heart medications, angiotensin-converting enzyme (ACE) inhibitors and beta blockers, can help to prevent a decline in heart function from breast cancer treatment, according to new research published in...

Two...

11/30/2016

Journal of Clinical Pathways

Research in Review

Combining Targeted Therapies Provides Optimal Treatment for CML

11/17/2016

JCP Editors

Using mathematical modeling, researchers have determined the best combination and sequencing of targeted therapies for the treatment of chronic myeloid leukemia (CML). Their results have been published in PLOS...

Using...

11/17/2016

Journal of Clinical Pathways

Research in Review

NET Equally Effective, Safer Than Neoadjuvant Chemotherapy for ER+ Breast Cancer

11/11/2016

JCP Editors

Neoadjuvant endocrine therapy may be just as effective as neoadjuvant chemotherapy for patients with localized, estrogen-receptor (ER)-positive breast cancer with considerably fewer adverse events, according to a...

...

11/11/2016

Journal of Clinical Pathways

Research in Review

Primary Prophylaxis for Breast Cancer Offers Little Benefit

11/07/2016

JCP Editors

The use of white blood cell growth stimulating factor drugs to reduce risk of neutropenia-related complications in women with breast cancer receiving common first-cycle chemotherapies had only a low-to-modest benefit...

The...

11/07/2016

Journal of Clinical Pathways